REG - Ondine Biomedical - Notice of Results, Investor Presentation, and AGM

Ondine BiomedicalAnnouncement

28/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240528:nRSb9640Pa&default-theme=true

RNS Number : 9640P  Ondine Biomedical Inc.  28 May 2024

28 May 2023

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of Results, Investor Presentation, and AGM

Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited
results for the year ended 31 December 2023 ("Full Year Results") and Annual
Report 2023 on 7 June 2024. Dr. Nicolas Loebel, President and Chief Technology
Officer of the Company, will provide a live presentation relating to the Full
Year Results via Investor Meet Company on 10 June 2024, 16:30 BST (08:30
Pacific time).

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until 9
June 2024, 09:00 BST (01:00 Pacific time), or at any time during the live
presentation.

Investors can sign up to Investor Meet Company for free and add to meet ONDINE
BIOMEDICAL INC. via:
https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
(https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor)

Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet
Company platform will automatically be invited.

A full overview of the 2023 fiscal year will be presented in the Annual Report
2023, which will be available on the Company's website on 7 June 2024. at:
www.ondinebio.com/investors/reports-documentation/. The slides and recording
of the live presentation will be posted to the same webpage as soon as
available following the presentation, no later than 11 June 2024.

The Company's 2024 Annual General Meeting is being held virtually on 28 June
2024 at 16:00 BST (08:00 Pacific time); registered shareholders and their duly
appointed proxyholders can attend the Meeting online via the link being
provided in the Notice of Meeting.

 

 Ondine Biomedical Inc.
 Angelika Vance, Corporate Communications                                                                    +001 (1) 604 838 2702

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Sam                                                                                          +44 (0)20 7496 3000
 Butcher

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                                                                              +44 (0) 20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                                                                            +44 (0) 77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Ondine's nasal photodisinfection technology is approved
in several jurisdictions under the brand name Steriwave ™. It has been
awarded the CE mark and, in the US, has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDDGDUXDDDGSR